Previous Article | Next Article 
J Virol, April 1998, p. 3066-3071, Vol. 72, No. 4
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
A Novel Membrane Protein Is a Mouse Mammary
Tumor Virus Receptor
Tatyana V.
Golovkina,1,
John
Dzuris,1
Bernadette
van
den Hoogen,1
Aron B.
Jaffe,1
Paul C.
Wright,2
Shelagh M.
Cofer,2 and
Susan
R.
Ross1,*
Department of Microbiology/Cancer Center,
University of Pennsylvania, Philadelphia, Pennsylvania
19104-6142,1 and
Department of
Biochemistry, University of Illinois School of Medicine, Chicago,
Illinois 606122
Received 1 August 1997/Accepted 23 December 1997
 |
ABSTRACT |
Mouse mammary tumor virus (MMTV) infects a number of different cell
types, including mammary gland and lymphoid cells, in vivo. To identify
the cellular receptor for this virus, a mouse cDNA expression
library was transfected into Cos-7 monkey kidney cells, and those
transfected cells able to bind virus were selected by using antibody
against the virus's cell surface envelope protein, gp52. One clone
isolated from a library prepared from newborn thymus RNA, called MTVR,
was able to confer virus binding to both monkey and human cells; this
binding was blocked by anti-MTVR antibody. Moreover, transfection of
MTVR into CV1 cells rendered them susceptible to infection by a murine
leukemia virus-based retrovirus vector pseudotyped with the MMTV
envelope protein. An epitope-tagged MTVR cofractionated with cellular
membranes. Coimmunoprecipitation of the MMTV envelope protein and a
MTVR-rabbit Fc fusion protein showed that these two proteins bound to
each other. The MTVR sequence clone is unique, shows no homology to known membrane proteins, and is transcribed in many tissues.
 |
INTRODUCTION |
Mouse mammary tumor virus (MMTV) is
a causative agent of mammary carcinomas in vivo and is acquired as an
exogenous virus when newborns suckle on the milk of viremic mothers
(14). Like other retroviruses, MMTV encodes an envelope
protein, consisting of two chains generated by processing a precursor
polyprotein, a cell surface (SU) domain of 52 kDa and a transmembrane
domain of 36 kDa (22). It is the SU protein that binds the
cellular receptor for the virus, since anti-SU antibody blocks MMTV
infection of cultured cells (10).
Although the ultimate target for MMTV is the mammary gland, cells of
the immune system play a role in milk-borne virus infection (2, 7, 9; for a review, see reference
16). MMTV encodes a superantigen protein in its long
terminal repeat that is presented by the major histocompatibility
complex class II proteins and interacts with the V
portion of the
T-cell receptor (reviewed in reference 16). During
the course of milk-borne MMTV transmission, the virus is first acquired
by B cells in the Peyer's patches (2, 9). These B cells act
as antigen-presenting cells and present the superantigen to T cells.
Subsequent to the activation of the B and T cells, both types become
MMTV infected and are capable of shedding virions, at least in vitro
(5). Whether both B and T cells transmit virus to the
mammary gland has not yet been resolved, since adoptive transfer
studies of the different lymphocyte subsets from infected mice into
nude mice indicated that only T cells transmitted virus
(20), whereas similar studies with immunocompetent mice
showed that transfer of either B or T cells resulted in transmission of
the virus to both cell types of an uninfected host (21).
In spite of our knowledge of the cell types involved in transmission of
MMTV from milk to the mammary gland, the molecular steps involved in
this process have not yet been elucidated. For example, it is not known
how the virus gets into the cells of the lymphoid system or how it is
transferred to mammary gland cells. One critical component of this
process is the cellular receptor, the molecule(s) present on the cell
surface that binds to the viral envelope protein. Previously, it has
been shown that the MMTV receptor maps to chromosome 16 in the mouse
(10). It was also reported that MMTV virions could bind to
cells from many different tissues, but that mammary gland and spleen
were able to bind higher amounts than salivary gland, ovary, adrenal
gland, and liver (3). If this binding activity represents
virus interaction with the actual MMTV receptor, mammary gland and
lymphoid cells might be the most efficiently infected because they have
the highest receptor levels.
To identify the cellular receptor for MMTV, we used virus binding to
cells transfected with a mouse cDNA expression library to enrich
for clones that coded for this receptor. Using this method, we isolated
the gene for a novel membrane-associated protein that confers both MMTV
binding and infectability. This gene, which is also found in humans and
other mammals, not only is likely to be important for MMTV infection of
mice but also must play a role in normal cell function.
 |
MATERIALS AND METHODS |
Receptor cloning.
A cDNA library was prepared from RNA
isolated from the thymi of Swiss Webster mice in the pcDNA1 vector
(Stratagene, Inc., La Jolla, Calif.), containing the cytomegalovirus
(CMV) promoter and simian virus 40 origin of replication, using the
Superscript plasmid system (Gibco/BRL, Bethesda, Md.). A total of
2 × 106 independent clones were transfected into
Cos-7 cells by spheroplast fusion (1). After transfection,
the cells were incubated first with MMTV(C3H) particles (0.5 µg/ml)
at 37°C for 1 h and then washed and incubated with monospecific
goat anti-SU polyclonal antiserum (8) for 1 h on ice.
The transfected cells which bound virus were isolated by panning on
dishes coated with rabbit anti-goat polyclonal antiserum as described
previously (1). DNA was isolated by Hirt fractionation from
the transfected cells, amplified in bacteria, and retransformed into
Cos-7 cells by spheroplast fusion. After six rounds of selection,
individual clones were isolated. All of the clones were individually
transiently transfected into Cos-7 or stably transfected into CV1 cells
along with a hygromycin resistance gene. The MTVR clone was also stably
transfected into the human mammary carcinoma line T47D with a plasmid
bearing the neomycin resistance gene and selected in G418.
Virus binding assay.
The different cell lines (Cos-7, CV1,
T47D, BT474, MCF-7, transiently transfected Cos-7, and stably
transfected CV1 and T47D) were briefly incubated in
[3H]thymidine (Fig. 1A) or
[35S]methionine (Fig. 1B and C) and removed from the
plates with EDTA (1 mM). The labeled cells were incubated with or
without MMTV(C3H) followed by goat anti-SU antibody and panned on
plates coated with rabbit anti-goat antiserum as described above. After extensive washing, the cells remaining on the plate were removed with
detergent and the number of counts per minute bound was determined.
Production of the His-tagged bacterial protein and antiserum
production.
To make anti-MTVR antisera, the cDNA was cloned
into the pET vector (Novagen, Inc., Madison, Wis.) and transfected into
Escherichia coli, and bacterially produced His-tagged fusion
protein was purified on nickel-agarose columns as specified by the
manufacturer (Qiagen, Inc.). The purified protein was injected into
rabbits by Cocalico, Inc. (Reamstown, Pa.), and the bleeds were tested
for the ability to recognize the bacterially produced protein by
Western blotting. For the blocking experiments, the ammonium
sulfate-precipitated immunoglobulin G (IgG) fraction was used at the
indicated concentrations.
Pseudotyped MLV virion production.
The pseudotyped murine
leukemia viruses (MLVs) were created by transient transfection of 293T
cells with plasmids pHIT111 (containing the MLV packaging sequence and
the lacZ gene), pHIT60 (containing the MLV
gag-pol genes under the control of the CMV promoter), and
pENV [containing the MMTV(C3H) envelope gene under the control of the
CMV promoter] (4) and used for infection of CV1-MTVR cells
as described by Soneoka et al. (19). Virions lacking
envelope protein were produced by 293T cells cotransfected with pHIT111
and pHIT60 alone and used as controls for infection.
Coimmunoprecipitation of Env and MTVR/Ig.
The MTVR coding
region was amplified by PCR and ligated in frame with the rabbit IgG
heavy-chain Fc coding region (25; a gift from John
Young) in the pcDNA1 expression vector. This plasmid was transfected
into 293T cells either alone or with the pEnv plasmid described above.
The cells were lysed in radioimmunoprecipitation assay buffer without
sodium dodecyl sulfate or deoxycholate and immunoprecipitated with
either goat anti-MMTV antiserum (Quality Biotech., Inc., Camden, N.J.),
anti-MTVR antiserum, or protein A-Sepharose (Gibco/BRL). After blotting
onto nitrocellulose membranes, the Env protein was detected with goat
anti-MMTV followed by horseradish peroxidase-conjugated mouse anti-goat
antiserum and enhanced chemiluminescence reagents as recommended by the
manufacturer (Amersham, Inc.).
Cell fractionation.
A T7 tag from the pET28 vector (Novagen)
was ligated in frame to the N terminus of the MTVR cDNA, and the
construct was subcloned into pcDNA1. The plasmid was transiently
transfected into 293T cells, and the cells were fractionated by
previously described methods (15). Equal amounts of protein
(50 µg) from each of the different fractions were trichloroacetic
acid precipitated, subjected to electrophoresis sodium dodecyl
sulfate-12% polyacrylamide gels, and analyzed by Western blotting.
Immunoprecipitations, immunohistochemistry, and Western
blots.
The anti-His-tagged-MTVR polyclonal antiserum was used to
immunoprecipitate [35S]methionine-labeled protein
synthesized by using an in vitro transcription-translation kit
(Gibco/BRL). Western blot analysis was performed with a monoclonal
antibody against the T7 epitope (Novagen) on the tagged MTVR protein.
For immunohistochemistry, HeLa cells were transiently transfected with
the T7-tagged MTVR, fixed with 4% paraformaldehyde, and stained with
the anti-T7 monoclonal antibody or a monoclonal antibody against the
transferrin receptor (a kind gift from Morrie Birnbaum).
 |
RESULTS |
Cloning of the MMTV receptor.
The first step in viral entry is
binding of the virus to a cell surface protein. To clone the MMTV
receptor, we used a modification of the technique developed by Aruffo
and Seed (1, 18) to look for a cloned protein that
would confer virus binding to cells. A cDNA expression library
prepared from newborn mouse thymus was transfected into Cos-7 cells,
which cannot be infected with MMTV (not shown). The transfected cells
were first incubated with purified MMTV and then panned with an
anti-MMTV polyclonal antibody. Plasmid DNA was isolated from the Cos-7
cells that bound to the plates, amplified, and retransfected into Cos-7
cells. After six rounds of transfection and panning, plasmid DNAs from
the bound Cos-7 cells were individually introduced into Cos-7 or CV1
(monkey kidney) cells by transient or stable transfection,
respectively. Approximately 10 different clones were tested in this
manner.
The cells transfected with the individual plasmids were tested for the
ability to bind to MMTV virions. As can be seen in Fig.
1A, when the NMuMG murine mammary gland
cell line, which can be infected by MMTV, was subjected to this
analysis, there were approximately three times more cells bound in the
presence of MMTV. In contrast, with Cos-7 cells, there was no binding
of MMTV, since equal numbers of cells bound to the antibody coated plates in the presence or absence of virus. When the cloned cDNAs were subjected to this analysis, only 1 (44T) of the 10 clones isolated
from the thymus cDNA library was able to confer binding of virus to
transiently transfected Cos-7 cells (Fig. 1A) or to stably transfected
CV1 cells (Fig. 1B). In both cases, the ratio of bound to unbound cells
in the presence and absence of virus was similar to what was seen with
the NMuMG cells. No other clones identified in the library conferred
binding of MMTV to either Cos-7 cells, as shown for osteopontin, or CV1
cells, as shown for apolipoprotein D (ApoD). These data showed that
44T conferred virus binding to cells that could not be infected with
virus; hereafter it is called MTVR.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 1.
Expression cloning of the MMTV receptor. (A) Virus
binding to NMuMG, Cos-7, and 44T(MTVR)- and osteopontin-transiently
transfected Cos-7 cells. (B) Virus binding to NMuMG and MTVR- and
ApoD-stably transfected CV1 cells. (C) Anti-44T antibody blocking of
binding to NMuMG cells. A 1:600 dilution of immune (+ab) or preimmune
(+PI) serum was used.
|
|
MTVR confers MMTV infectability.
To determine if expression of
MTVR also made the CV1 cells permissive for virus infection, we created
a pseudotyped MLV-based retroviral vector with the MMTV envelope
proteins. The MTVR-transfected CV1 cells were infected with these
pseudotyped viruses. Both of the mouse mammary gland cell lines, NMuMG
and MTVR-transfected CV1, but not the ApoD-transfected cells were
infected with the pseudotyped viruses (Fig.
2). Thus, MTVR is a bona fide MMTV
receptor.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Infection of MTVR-transfected CV1 cells by MLV
pseudotyped with MMTV envelope proteins. The numbers of
-galactosidase-positive colonies from three independent
transfections were averaged; shown are the average numbers with
standard deviations.
|
|
MTVR is a novel protein.
The complete nucleotide and
predicted amino acid sequences of the cloned MTVR cDNA are shown in
Fig. 3A. The clone is 1,141 nucleotides
in length, excluding the poly(A) tail. By low-stringency Southern
blot analysis, homologous sequences were seen in all mammalian
species examined but not in Drosophila or birds (not shown). When either the amino acid or nucleic acid sequence of MTVR was compared to entries in GenBank, no homology to any known gene was found, using either the Blast or the FastA algorithm. However,
partial clones of MTVR were recently cloned from both mouse and
human fetal liver EST (expressed sequence tag) libraries. The region of
the human gene cloned (approximately 733 bp) showed 83.5% homology at
the nucleotide level (not shown) and 86% homology in the predicted
protein sequence (Fig. 3B). However, previous studies, including
our own, have shown, that MMTV does not infect human cells (11,
16a, 24). For example, as seen in Fig.
4, no human mammary carcinoma cultured
cells (T47D, MCF-7, and BT474) bound MMTV although they all
produced an MTVR-hybridizing transcript (not shown). However, when the
T47D cell line was transfected with the mouse MTVR clone, virus binding
was detected. These results imply that the differences in the amino
acid sequence of the human MTVR alter its ability to interact with the
MMTV envelope protein.

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 3.
Sequence of MTVR. (A) Nucleotide and predicted amino
acid sequences of MTVR cDNA. The overlined amino acids indicate the
hydrophobic domain. Underlined G's represent putative myristoylation
sites; the italicized N represents a potential N-glycosylation site.
The sites were determined by using the PROSITE program. The overlapping
putative polyadenylation signals are double underlined. (B) Homology
between the mouse (M) and human (H) MTVR coding regions. The human
sequence was derived from sequences under accession no. T95780 and
H68224 in the EST database.
|
|

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 4.
MMTV binding to human mammary carcinoma cell lines.
MCF-7, BT474, T47D, and T47D/MTVR cells were panned with anti-MMTV
antibody as described in Materials and Methods.
|
|
A Kyte-Doolittle hydrophobicity plot of the predicted MTVR
protein indicates that there is one hydrophobic domain (amino acids
[aa] 10 to 28) (
12). There are one putative N-linked
glycosylation
site (aa 32), three O-linked glycosylation sites (aa 7, 129, and
147), and six putative myristoylation sites (aa 11, 12, 14, 26,
29, 70, and 100).
We screened an independent cDNA library with MTVR cDNA probe
and isolated a clone that had an additional 15 nucleotides at
the 5'
end; moreover, using rapid amplification of cDNA ends to
amplify
the 5' end, we showed that the bona fide mRNA contained
these
additional nucleotides (not shown). The cDNA contains a
single contiguous open reading frame that codes for a protein
of 18,704 Da. The protein is shown initiating at the first in-frame
methionine in
Fig.
3A; this AUG conforms to the Kozak consensus
sequence rules, and
in vitro transcription-translation studies
indicate that the protein is
approximately this size (see below).
However, the open reading frame
continues upstream of this first
methionine. Because there are two
transcripts that hybridize to
the MTVR cDNA probe in some tissues
(see below), it is possible
that there is more than one form of the
protein.
MTVR is found on the cell surface.
A
histidine-tagged MTVR bacterial fusion protein was constructed,
and a polyclonal rabbit antiserum against this protein was made. In
vitro transcription-translation of MTVR indicates that it encodes
an approximately 19-kDa protein that is immunoprecipitated by the
anti-MTVR polyclonal antiserum (Fig. 5A).
This antiserum blocked binding of the virus to NMuMG cells, while
preimmune serum from the same rabbit did not (Fig. 1C).
However, we have been unable to detect endogenous protein by Western
blot or immunoprecipitation analyses, indicating that the expression
levels are low.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 5.
(A) Immunoprecipitation of in vitro-transcribed,
translated MTVR. Sizes are indicated in kilodaltons. (B) Cell
fractionation studies. Lanes: Ext., total extract; Ext. + Try., extract
from trypsin-treated cells; N, nuclear pellet; S, S100 supernatant; P,
S100 pellet; CO3 S, supernatant from carbonate-extracted S100 pellet;
CO3 P, pellet from carbonate-extracted S100 pellet.
|
|
To prove that the MTVR was found on the cell surface, as is predicted
for a viral receptor, we epitope tagged the cDNA at
the N terminus
with a peptide from the T7 gene. This construct
was put into a
mammalian expression vector (pcDNA1) and transiently
transfected
into 293T cells. Western blot analysis using a monoclonal
antibody
against the T7 epitope (Fig.
5B, lane 1) or the anti-His-tagged
MTVR
(not shown) detected this protein. Cell fractionation studies
of
293T cells transiently transfected with the MTVR, including
carbonate
extraction of the S100 pellet, showed that the tagged
cDNA
copurified with a known transmembrane protein, the transferrin
receptor in the membrane fraction (Fig.
5B). Trypsin treatment
of the
transfected cells greatly diminished the amount of MTVR
and the
transferrin receptor (Fig.
5B) but not the simian virus
40 large T
protein made in these cells (not shown).
We also performed immunohistochemistry to show that the MTVR is a cell
surface protein. HeLa cells were transiently transfected
with the
T7-tagged MTVR construct and fixed but not permeabilized.
The
cells were stained with an anti-T7 monoclonal antibody (Fig.
6A) or an anti-transferrin receptor
antibody (Fig.
6B). Whereas
all cells showed cell surface staining for
the transferrin receptor,
only those cells that were transfected
stained with the anti-T7
antibody. Taken together, these results
indicate that the N terminus
of the MTVR is located on the cell
exterior.

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 6.
Immunohistochemistry of MTVR-transfected cells. HeLa
cells were transiently transfected with the T7-tagged MTVR construct,
fixed with 4% paraformaldehyde, and stained with anti-T7 antibody (A)
or anti-transferrin receptor antibody (B).
|
|
The MTVR clone binds the MMTV envelope proteins.
To determine
whether the MTVR clone bound to the MMTV envelope proteins, we
constructed an immunoadhesin in which the entire MTVR was inserted
upstream of the rabbit IgG Fc coding region in a mammalian expression
vector (MTVR/Ig). This construct was transiently transfected into 293T
cells either alone or with a plasmid containing the coding region for
the MMTV gp73 polyprotein precursor to the gp52 and gp36 proteins.
Crude cell extracts were prepared and precipitated either with
anti-MTVR antiserum, anti-MMTV antiserum, or protein A-Sepharose alone.
In all three cases, the envelope precursor protein gp73 was detected
(Fig. 7). In contrast, neither anti-MTVR
antiserum nor protein A-agarose was able to precipitate the Env protein
in the absence of MTVR protein. The gp52 protein is difficult to
detect in these immunoprecipitations because the MTVR immunoadhesin and
goat anti-MMTV antibodies migrate at the same apparent molecular
weight. The MTVR/Ig protein also bound the Env proteins when the
extracts from cells separately transfected with these plasmids were
mixed together (not shown). Thus, the MTVR protein binds to MMTV
envelope proteins.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 7.
Coimmunoprecipitation of the MMTV envelope protein and
MTVR/Ig. 293T cells were transfected either separately or together with
plasmids containing the MMTV envelope coding region (Env) and the
MTVR/Ig construct. Lysates prepared from these cells were
immunoprecipitated either with goat anti-MMTV antiserum followed by
rabbit anti-goat immunoglobulin (MMTV) or rabbit anti-MTVR antisera
(MTVR) or with protein A-agarose alone (Prot. A). Western blot analysis
was carried out with goat anti-MMTV antiserum followed by horseradish
peroxidase-linked mouse anti-goat antibodies and enhanced
chemiluminescence detection. The gp73 protein is the envelope
polyprotein precursor. Because the gp52 SU protein is about 10-fold
less abundant in the cells and migrates at approximately the same
apparent molecular weight as the goat anti-MMTV antibody (goat Ab) and
MTVR/Ig proteins, it is obscured on these gels.
|
|
MTVR is ubiquitously transcribed.
MMTV infects only a limited
number of cell types in vivo and in vitro (16). To
determine in which tissues the receptor was transcribed, we hybridized
the MTVR cDNA clone to Northern blots containing RNA from different
tissues (Fig. 8). The receptor mRNA was widely expressed, and two transcripts were detected in some tissues
(e.g., brain and testis lanes in Fig. 8).

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 8.
Northern blot analysis of MTVR RNA from different
tissues. Twenty-microgram aliquots of total RNA from the tissues
and cell lines were analyzed. Abbreviations: VMG, virgin mammary gland;
LMG, lactating mammary gland; LN, lymph node; SG, salivary gland.
|
|
MTVR maps to chromosome 19.
To determine the chromosomal
location of the MTVR, we used DNAs from a panel of 93 animals
([C57BL6/Ei × SPRET/Ei] × SPRET/Ei backcross panel) from the
Jackson Laboratory to map the MTVR chromosomal location
(17). This analysis mapped MTVR (Mtvr2) to the proximal end
of chromosome 19 (Fig. 9).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 9.
Haplotype figure for the MTVR-mapping data from the
proximal part of chromosome 19 from the Jackson Laboratory BSS
backcross panel. Loci are listed in the left column in order with the
centromere at the top. Black boxes represent the C57BL/6J allele, and
white boxes represent the SPRET/Ei allele. The number below each column
of boxes indicates the number of N2 animals with that haplotype. R is
recombination frequency in each interval, and SE is the standard error
for that R.
|
|
 |
DISCUSSION |
The method used to clone the MMTV receptor, MTVR, relied on both
virus binding to cells and the recognition of virus by antibodies. MMTV
virion stocks have many noninfectious particles, and there is no assay
for detecting MMTV infection of single tissue culture cells. Moreover,
it is difficult to obtain high-titer recombinant MMTVs. These technical
difficulties have previously prevented the identification of the
receptor for this virus. These problems were circumvented here, since
high infectious virus titers were not required to assay for binding.
This technique should be applicable to other viruses for which similar
low titers and lack of biological assays have prevented identification
of the receptor.
RNA tumor viruses exhibit a high degree of host range and cell type
specificity. This specificity is partially determined by the presence
of the appropriate cell surface receptors on target cells. MMTV is
different from most other murine retroviruses in that it infects only a
limited range of cell types. However, we showed that the MTVR is
ubiquitously expressed, at least at the RNA level. The lack of
infectivity could be due to variable levels of receptor protein in
different cell types. It is also possible that there are post-receptor
binding steps that are blocked in some cell types. Alternatively, MMTV
may utilize a coreceptor for membrane fusion that is not ubiquitously
present.
Another block to tissue-specific infection by MMTV is at the
transcriptional level. It has been shown that MMTV expresses only in
mammary gland epithelial cells, lymphoid cells, and a few other
epithelial cell types (for a review, see reference
16). Thus, even if MMTV infects and integrates into
the chromosomes of cell types besides the mammary gland, expression of
the virus may not occur and infection of the tissue would be limited.
Whether MTVR is the only receptor for the virus on all permissive cell types (i.e., lymphoid and mammary gland cells) will be addressed in
future experiments, using antibody blocking and targeted mutagenesis.
The MMTV receptor was previously mapped to mouse chromosome 16, using
vesicular stomatitis virus pseudotypes containing envelope glycoproteins to infect mouse-hamster somatic cell hybrids
(10). In this study, we found that the MTVR maps to the
proximal end of chromosome 19. Either there is more than one receptor
for MMTV or the original mapping of the receptor to chromosome 16 was
incorrect; these studies used only one marker per chromosome, and there
may have been recombination events in the somatic cell hybrids. In support of this, the presence of chromosome 19 in the mouse-hamster somatic cell hybrids showed the second-highest correlation with infectability in the MMTV/vesicular stomatitis virus pseudotypes, using
a marker that was located on the distal end of this chromosome.
Several retroviral receptors have been previously identified. At least
three of these receptors, the human immunodeficiency virus receptor CD4
and the avian sarcoma virus subgroup A and subgroup B receptors, have
single membrane-spanning domains, whereas a number of other retroviral
receptors have multiple membrane-spanning domains (reviewed in
reference 23). The MTVR identified here is unique
among retroviral receptors in that it is relatively small and it has no
strong homology to any known transmembrane protein. Thus,
MTVR-SU interactions may be different from those that occur between
other retroviral Env proteins and their receptors. For example, unlike
the case for other retroviruses, expression of endogenous MMTVs does
not appear prevent superinfection by exogenous MMTVs through a receptor
interference mechanism. GR mice have a functional endogenous MMTV,
Mtv-2, that is expressed in mammary gland, yet mammary
tumors that acquire multiple new virus integrants derived from
Mtv-2 arise in this mouse strain (13). In
addition, most MMTV-induced mammary tumors have multiple copies of
newly integrated proviruses, supporting a lack of receptor interference
for this virus. We have also shown that cultured mammary cells
transfected with a molecular clone of MMTV, HYB PRO, can be infected
with MLV pseudotypes containing the same HYB PRO Env on the virion
(6). How the MMTV envelope protein binds to this receptor is
therefore likely to provide new information about virus-cell
interactions.
Retroviruses take advantage of host-encoded cell surface proteins that
play important roles in cellular metabolism, and MTVR is likely to also
play such a role. The identification of the receptor for this virus
should allow us to determine not only the cellular function of this
novel protein but also the mechanism(s) by which MMTV binds and enters
cells, to determine how the cell type restriction occurs, and to
understand how this virus utilizes cells of both the immune system and
mammary gland in its infection pathway.
 |
ACKNOWLEDGMENTS |
The first three authors contributed equally to the work, which
was begun at the University of Illinois School of Medicine, Chicago.
We thank Hans Stauss for initially suggesting this approach for cloning
the receptor, Paul Gadeu for help with construction of the pENV
construct, Wei Zhu for help with the MTVR/Ig construct, Marta de Olano
Vela and Valsamma Abraham for technical assistance, Paul Bates and
Lijin Rong for the MLV packaging plasmids and for advice on creating
the pseudotyped virions, and Lucy Rowe for help with the chromosome
mapping analysis.
This work was supported by grants from the National Cancer Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology/Cancer Center, University of Pennsylvania, 526 CRB, 415 Curie Blvd., Philadelphia, PA 19104-6142. Phone: (215) 898-9764. Fax:
(215) 573-2028. E-mail: rosss{at}mail.med.upenn.edu.
Present address: The Jackson Laboratory, Bar Harbor, Maine.
 |
REFERENCES |
| 1.
|
Aruffo, A., and B. Seed.
1987.
Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system.
Proc. Natl. Acad. Sci. USA
84:8573-8577[Abstract/Free Full Text].
|
| 2.
|
Beutner, U.,
E. Draus,
D. Kitamura,
K. Rajewsky, and B. T. Huber.
1994.
B cells are essential for murine mammary tumor virus transmission, but not for presentation of endogenous superantigens.
J. Exp. Med.
179:1457-1466[Abstract/Free Full Text].
|
| 3.
|
Bolander, F. F., and M. E. Blackstone.
1991.
Tissue distribution of the cellular binding protein for the mouse mammary tumor virus.
J. Endocrinol.
7:169-174.
|
| 4.
| Dzuris, J. Unpublished data.
|
| 5.
|
Dzuris, J.,
T. Golovkina, and S. R. Ross.
1997.
Both T and B cells shed infectious mouse mammary tumor virus.
J. Virol.
71:6044-6048[Abstract].
|
| 6.
| Dzuris, J. L., W. Zhu, T. V. Golovkina, and
S. R. Ross. Unpublished data.
|
| 7.
|
Golovkina, T. V.,
A. Chervonsky,
J. P. Dudley, and S. R. Ross.
1992.
Transgenic mouse mammary tumor virus superantigen expression prevents viral infection.
Cell
69:637-645[Medline].
|
| 8.
|
Golovkina, T. V.,
A. Chervonsky,
J. A. Prescott,
C. A. Janeway, and S. R. Ross.
1994.
The mouse mammary tumor virus envelope gene product is required for superantigen presentation to T cells.
J. Exp. Med.
179:439-446[Abstract/Free Full Text].
|
| 9.
|
Held, W.,
G. Waanders,
A. N. Shakhov,
L. Scarpellino,
H. Acha-Orbea, and H. Robson-MacDonald.
1993.
Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission.
Cell
74:529-540[Medline].
|
| 10.
|
Hilkens, J.,
B. van der Zeust,
F. Buijs,
V. Kroezen,
N. Bluemink, and J. Hilgers.
1983.
Identification of a cellular receptor for mouse mammary tumor virus and mapping of its gene to chromosome 16.
J. Virol.
45:140-147[Abstract/Free Full Text].
|
| 11.
|
Howard, D. K., and J. Schlom.
1980.
Isolation of a series of novel variants of murine mammary tumor viruses with broadened host range.
Int. J. Cancer
25:647-654[Medline].
|
| 12.
|
Kyte, J., and R. F. Doolittle.
1982.
A simple method for displaying the hydropathic character of a protein.
J. Mol. Biol.
157:105-132[Medline].
|
| 13.
|
Michalides, R.,
L. van Deemter,
R. Nusse, and R. van Nie.
1978.
Identification of the Mtv-2 gene responsible for early appearance of mammary tumors in the GR mouse by nucleic acid hybridization.
Proc. Natl. Acad. Sci. USA
75:2368-2372[Abstract/Free Full Text].
|
| 14.
|
Nandi, S., and C. M. McGrath.
1973.
Mammary neoplasia in mice.
Adv. Cancer Res.
17:353-414.
|
| 15.
|
Platt, E. J., and G. L. Firestone.
1991.
Expression of mouse mammary tumor virus glycoprotein trucations defines roles for the transmembrane domain and ectodomain hydrophobic region in constitutive exocytic trafficking and proteolytic processing.
J. Biol. Chem.
266:19384-19395[Abstract/Free Full Text].
|
| 16.
|
Ross, S. R.
1996.
MMTV and the immune system.
Adv. Pharmacol.
37:21-46.
|
| 16a.
| Ross, S. R., et al. Unpublished data.
|
| 17.
|
Rowe, L. B.,
J. H. Nadeau,
R. Turner,
W. N. Frankel,
V. A. Letts,
J. T. Eppig,
M. S. H. Ko,
S. J. Thurston, and E. H. Birkenmeier.
1994.
Maps from two interspecific backcross DNA panels available as a community genetic mapping resource.
Mamm. Genet.
5:253-274.
|
| 18.
|
Seed, B., and A. Aruffo.
1987.
Molecular cloning of the CD2 antigen, the T cell erythrocyte receptor by rapid immunoselection procedure.
Proc. Natl. Acad. Sci. USA
84:3365-3369[Abstract/Free Full Text].
|
| 19.
|
Soneoka, Y.,
P. M. Cannon,
E. E. Ramsdale,
J. C. Griffiths,
G. Romano,
S. M. Kingsman, and A. J. Kingsman.
1995.
A transient three-plasmid expression system for the production of high titer retroviral vectors.
Nucleic Acids Res.
23:628-633[Abstract/Free Full Text].
|
| 20.
|
Tsubura, A.,
M. Inaba,
S. Imai,
A. Murakami,
N. Oyaizu,
R. Yasumizu,
Y. Ohnishi,
H. Tanaka,
S. Morii, and S. Ikehara.
1988.
Intervention of T-cells in transportation of mouse mammary tumor virus (milk factor) to mammary gland cells in vivo.
Cancer Res.
48:6555-6559[Abstract/Free Full Text].
|
| 21.
|
Waanders, G. A.,
A. N. Shakhov,
W. Held,
P. Karapetian,
H. Acha-Orbea, and H. R. MacDonald.
1993.
Peripheral T cell activation and deletion induced by transfer of lymphocyte subsets expressing endogenous or exogenous mouse mammary tumor virus.
J. Exp. Med.
177:1359-1366[Abstract/Free Full Text].
|
| 22.
|
Weiss, R.,
N. Teich,
H. Varmus, and J. Coffin.
1984.
RNA tumor viruses, p. 590-591. In
R. Weiss, N. Teich, and J. M. Coffin (ed.), Molecular biology of tumor viruses.
CSH Press, Cold Spring Harbor, N.Y.
|
| 23.
|
Weiss, R. A., and C. S. Tailor.
1995.
Retrovirus receptors.
Cell
82:531-533[Medline].
|
| 24.
|
Zavada, J.,
C. Dickson, and R. Weiss.
1977.
Pseudotypes of vesicular stomatitis virus with envelope antigens provided by murine mammary tumor virus.
Virology
82:221-331[Medline].
|
| 25.
|
Zingler, K., and J. A. T. Young.
1996.
Residue Trp-48 of Tva is critical for viral entry but not for high-affinity binding to the SU glycoprotein of subgroup A avian leukosis and sarcoma viruses.
J. Virol.
70:7510-7516[Abstract].
|
J Virol, April 1998, p. 3066-3071, Vol. 72, No. 4
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Okeoma, C. M., Low, A., Bailis, W., Fan, H. Y., Peterlin, B. M., Ross, S. R.
(2009). Induction of APOBEC3 In Vivo Causes Increased Restriction of Retrovirus Infection. J. Virol.
83: 3486-3495
[Abstract]
[Full Text]
-
Courreges, M. C., Burzyn, D., Nepomnaschy, I., Piazzon, I., Ross, S. R.
(2007). Critical Role of Dendritic Cells in Mouse Mammary Tumor Virus In Vivo Infection. J. Virol.
81: 3769-3777
[Abstract]
[Full Text]
-
Ross, S. R., Schmidt, J. W., Katz, E., Cappelli, L., Hultine, S., Gimotty, P., Monroe, J. G.
(2006). An immunoreceptor tyrosine activation motif in the mouse mammary tumor virus envelope protein plays a role in virus-induced mammary tumors.. J. Virol.
80: 9000-9008
[Abstract]
[Full Text]
-
Wang, E., Albritton, L., Ross, S. R.
(2006). Identification of the Segments of the Mouse Transferrin Receptor 1 Required for Mouse Mammary Tumor Virus Infection. J. Biol. Chem.
281: 10243-10249
[Abstract]
[Full Text]
-
Indik, S., Gunzburg, W. H., Salmons, B., Rouault, F.
(2005). Mouse Mammary Tumor Virus Infects Human Cells. Cancer Res.
65: 6651-6659
[Abstract]
[Full Text]
-
Ahmed, F., Torrado, M., Zinovieva, R. D., Senatorov, V. V., Wistow, G., Tomarev, S. I.
(2004). Gene Expression Profile of the Rat Eye Iridocorneal Angle: NEIBank Expressed Sequence Tag Analysis. IOVS
45: 3081-3090
[Abstract]
[Full Text]
-
Zhang, Y., Rassa, J. C., deObaldia, M. E., Albritton, L. M., Ross, S. R.
(2003). Identification of the Receptor Binding Domain of the Mouse Mammary Tumor Virus Envelope Protein. J. Virol.
77: 10468-10478
[Abstract]
[Full Text]
-
Chow, Y.-H. J., Alberti, A., Mura, M., Pretto, C., Murcia, P., Albritton, L. M., Palmarini, M.
(2003). Transformation of Rodent Fibroblasts by the Jaagsiekte Sheep Retrovirus Envelope Is Receptor Independent and Does Not Require the Surface Domain. J. Virol.
77: 6341-6350
[Abstract]
[Full Text]
-
Kokura, K., Kim, H., Shinagawa, T., Khan, M. M., Nomura, T., Ishii, S.
(2003). The Ski-binding Protein C184M Negatively Regulates Tumor Growth Factor-{beta} Signaling by Sequestering the Smad Proteins in the Cytoplasm. J. Biol. Chem.
278: 20133-20139
[Abstract]
[Full Text]
-
Ross, S. R., Schofield, J. J., Farr, C. J., Bucan, M.
(2002). Mouse transferrin receptor 1 is the cell entry receptor for mouse mammary tumor virus. Proc. Natl. Acad. Sci. USA
99: 12386-12390
[Abstract]
[Full Text]
-
Rassa, J. C., Meyers, J. L., Zhang, Y., Kudaravalli, R., Ross, S. R.
(2002). Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc. Natl. Acad. Sci. USA
99: 2281-2286
[Abstract]
[Full Text]
-
Overbaugh, J., Miller, A. D., Eiden, M. V.
(2001). Receptors and Entry Cofactors for Retroviruses Include Single and Multiple Transmembrane-Spanning Proteins as well as Newly Described Glycophosphatidylinositol-Anchored and Secreted Proteins. Microbiol. Mol. Biol. Rev.
65: 371-389
[Abstract]
[Full Text]
-
de Parseval, A., Elder, J. H.
(2001). Binding of Recombinant Feline Immunodeficiency Virus Surface Glycoprotein to Feline Cells: Role of CXCR4, Cell-Surface Heparans, and an Unidentified Non-CXCR4 Receptor. J. Virol.
75: 4528-4539
[Abstract]
[Full Text]
-
Sommerfelt, M. A.
(1999). Retrovirus receptors. J. Gen. Virol.
80: 3049-3064
[Full Text]
-
Baribaud, F., Vessaz Shaw, A., Scarpellino, L., Diggelmann, H., Acha-Orbea, H.
(1999). Preferential Binding of Mouse Mammary Tumor Virus to B Lymphocytes. J. Virol.
73: 7899-7902
[Abstract]
[Full Text]
-
Pogo, B. G-T., Melana, S. M., Holland, J. F., Mandeli, J. F., Pilotti, S., Casalini, P., Menard, S.
(1999). Sequences Homologous to the Mouse Mammary Tumor Virus env Gene in Human Breast Carcinoma Correlate with Overexpression of Laminin Receptor. Clin. Cancer Res.
5: 2108-2111
[Abstract]
[Full Text]
-
Grimm, S. L., Nordeen, S. K.
(1999). A Composite Enhancer Element Directing Tissue-specific Expression of Mouse Mammary Tumor Virus Requires both Ubiquitous and Tissue-restricted Factors. J. Biol. Chem.
274: 12790-12796
[Abstract]
[Full Text]
-
Battini, J.-L., Rasko, J. E. J., Miller, A. D.
(1999). A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: Possible role in G protein-coupled signal transduction. Proc. Natl. Acad. Sci. USA
96: 1385-1390
[Abstract]
[Full Text]